ifosfamide brands
3 registered brands containing ifosfamide in Botswana.
Ifosfamide
PubChem CID 3690Molecular formula: C7H15Cl2N2O2P
The exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA results in cell death. Mechanism of action: metabolites cause alkylation of DNA. /from table/ Ifosfamide, a structural analog of cyclophosphamide, belongs to the oxazaphosphorine class of antitumor alkylating agents which must be activated by the mixed function oxidase system of the liver. The 4-hydroxy oxazaphosphorines are a reactive species capable of interacting with nucleic acids & cellular materials to cause cell damage & death. The 4-hydroxy metabolite spontaneously liberates acrolein in many sites throughout the body & it is this substance that is responsible for oxazaphosphorine urotoxicity. Both ifosfamide & cyclophosphamide produce cystitis characterized by tissue edema & ulceration followed by sloughing of mucosal epithelial cells, necrosis of smooth muscle fibers & arteries, & culminating in focal hemorrhage. The selective urotoxicity of oxazaphosphorine occurs because the bladder contains a very low concn of thiol cmpds (glutathione, cysteine) which, by virtue of their nucleophilic sulfhydryl groups, are able to react & neutralize many reactive chemicals. Because the metabolic activation of ifosfamide proceeds more slowly than that of cyclophosphamide, doses of ifosfamide are 3-4 times higher than those of cyclophosphamide. This explains the higher incidence of urotoxicity associated with ifosfamide.
Source: PubChem (NCBI) ยท compound 3690
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| HOLOXAN 1G INJECTION DRY POWDER FOR INJECTION |
Baxter | Registered/Compliant | Botswana |
| HOLOXAN 2G INJECTION DRY POWDER FOR INJECTION |
Baxter | Registered/Compliant | Botswana |
| HOLOXAN 500 MG INJECTION DRY POWDER FOR INJECTION |
Baxter | Registered/Compliant | Botswana |